[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 61 of about 61
1. Bishara MR, Ross C, Sur M: Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation. Diagn Pathol; 2009;4:11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation.
  • BACKGROUND: Primary non-Hodgkin lymphoma (NHL) of the breast represents 0.04-0.5% of malignant lesions of the breast and accounts for 1.7-2.2% of extra-nodal NHL.
  • Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults with the breast being one of the least common locations.
  • There are a total of eleven cases of primary ALCL of the breast described in the literature.
  • Eight of these cases occurred in proximity to breast implants, four in relation to silicone breast implant and three in relation to saline filled breast implant with three out of the eight implant related cases having previous history of breast cancer treated surgically.
  • Secondary hematological malignancies after breast cancer chemotherapy have been reported in literature.
  • CASE PRESENTATION: In this report we present a case of primary ALCL of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for infiltrating ductal carcinoma followed by postoperative chemotherapy twelve years ago.
  • CONCLUSION: Primary ALK negative ALCL arising at the site of saline filled breast implant is rare.
  • It is still unclear whether chemotherapy and breast implantation increases risk of secondary hematological malignancies significantly.
  • However, it is important to be aware of these complications and need for careful pathologic examination of tissue removed for implant related complications to make the correct diagnosis for further patient management and treatment.
  • It is important to be aware of this entity at this site as it can be easily misdiagnosed on histologic grounds and to exclude sarcomatoid carcinoma, malignant melanoma and pleomorphic sarcoma by an appropriate panel of immunostains to arrive at the correct diagnosis of ALCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):723-6 [12033965.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):738-44 [12374656.001]
  • [Cites] Mod Pathol. 2000 Jun;13(6):599-605 [10874662.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2406-12 [10856100.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Diagn Cytopathol. 2006 Apr;34(4):298-302 [16544330.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1183-8 [16085560.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):37-42 [15989705.001]
  • [Cites] APMIS. 1997 Jun;105(6):445-8 [9236861.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1359-69 [1991299.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):244-56 [12876673.001]
  • [Cites] Ann Oncol. 2003 May;14(5):693-8 [12702521.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):115-6 [12562279.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • (PMID = 19341480.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678081
  •  go-up   go-down


2. Li S, Lee AK: Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol; 2009;3(1):117-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction?
  • A series of anecdotal case reports and a recent epidemiological case-control study have suggested a possible association between silicone implant and the development of primary breast ALK1-negative anaplastic large cell lymphoma (ALCL), a rare type of peripheral T-cell lymphoma.
  • In this report, we describe an additional case of primary breast ALK1-negative ALCL in the fibrous capsule and cystic fluid of silicone breast implant in a 58 year old woman who underwent breast reconstructive surgery after lumpectomy for her infiltrating breast adenocarcinoma.
  • Morphologically and immunohistochemically, the lymphoma cells may be confused with recurrent infiltrating breast adenocarcinoma or other non-hematolymphoid malignancies.
  • We will also review the case reports and case series published in the English literature and discuss our current understanding of silicone implant in primary breast ALK1-negative ALCL.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Breast Implants / adverse effects. Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Diagnosis, Differential. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Reconstructive Surgical Procedures

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):407-13 [18480397.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):133-9 [19199367.001]
  • [Cites] Plast Reconstr Surg. 2009 Mar;123(3):790-3 [19319041.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):831-3 [19330656.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):918-24 [19373599.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):301-6 [19318917.001]
  • [Cites] Clin Breast Cancer. 2009 Aug;9(3):145-54 [19661037.001]
  • [Cites] Ann Oncol. 2009 Dec;20(12):1993-9 [19570964.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Epidemiology. 2001 May;12(3):321-6 [11337605.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Haematologica. 2004 Apr;89(4):ELT01 [15075114.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):939-42 [7751462.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1341-9 [9308703.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):557-60 [16622125.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Int J Hematol. 2008 Jun;87(5):491-7 [18414980.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):822-5 [17509956.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • (PMID = 19918336.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Other-IDs] NLM/ PMC2776268
  • [Keywords] NOTNLM ; ALCL / ALK1 / Breast implant / anaplastic large cell lymphoma / silicone
  •  go-up   go-down


3. Palmer RH, Vernersson E, Grabbe C, Hallberg B: Anaplastic lymphoma kinase: signalling in development and disease. Biochem J; 2009 Jun 15;420(3):345-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase: signalling in development and disease.
  • The ALK (anaplastic lymphoma kinase) RTK was originally identified as a member of the insulin receptor subfamily of RTKs that acquires transforming capability when truncated and fused to NPM (nucleophosmin) in the t(2;5) chromosomal rearrangement associated with ALCL (anaplastic large cell lymphoma).
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Models, Biological. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neuroblastoma / pathology. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Receptor Protein-Tyrosine Kinases

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2007 Jul 15;176(2):107-14 [17656252.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1580-1 [15317731.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5405-15 [15466886.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] J Antibiot (Tokyo). 1989 Apr;42(4):571-6 [2656615.001]
  • [Cites] Eur J Biochem. 1989 Dec 22;186(3):733-40 [2558016.001]
  • [Cites] J Biol Chem. 1990 Jun 25;265(18):10765-70 [2355021.001]
  • [Cites] EMBO J. 1990 Jul;9(7):2279-87 [2357970.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):16721-4 [2170351.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Oct 30;172(2):850-4 [1700712.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Nov 30;173(1):246-51 [1701634.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Oct 15;180(1):145-51 [1819274.001]
  • [Cites] Anat Embryol (Berl). 1992 Sep;186(4):387-406 [1416088.001]
  • [Cites] Biochem Int. 1992 Oct;28(1):1-9 [1445382.001]
  • [Cites] Trends Biochem Sci. 1993 Feb;18(2):40-1 [8387703.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12999-3004 [8175719.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1567-74 [8183550.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1584-90 [7520350.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 15;203(2):1131-9 [8093031.001]
  • [Cites] Neurosci Lett. 1994 Sep 12;178(2):216-20 [7824199.001]
  • [Cites] Development. 1995 Jan;121(1):37-51 [7867507.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):309-14 [7533562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62 [7708684.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6334-8 [7603991.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):590-4 [8666370.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21446-52 [8702927.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] J Biochem. 1997 Feb;121(2):197-205 [9089390.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16733-6 [9201975.001]
  • [Cites] Nature. 1997 Aug 14;388(6643):691-3 [9262405.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Adv Exp Med Biol. 1998;431:221-6 [9598063.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):781-6 [12855999.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5399-407 [12934099.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1138-44 [9886332.001]
  • [Cites] Genes Cells. 1998 Dec;3(12):811-22 [10096022.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 May 1;93(9):3088-95 [10216106.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] J Thorac Surg. 1954 Jul;28(1):55-63 [13175281.001]
  • [Cites] Blood. 2005 Jan 15;105(2):827-9 [15374880.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] Mutat Res. 2005 Feb 15;570(1):9-15 [15680399.001]
  • [Cites] Nat Med. 2005 Jun;11(6):623-9 [15895073.001]
  • [Cites] Biochemistry. 2005 Jun 14;44(23):8533-42 [15938644.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):213-22 [15972965.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):714-21 [15985215.001]
  • [Cites] Haematologica. 2005 Jul;90(7):988-90 [15996942.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26039-48 [15886198.001]
  • [Cites] Cell. 2005 Jul 15;122(1):45-57 [16009132.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26953-64 [15908427.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1128-34 [15902287.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3191-6 [16101126.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):939-44 [16153455.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):796-801 [15602716.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):942-51 [15986444.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Dec;315(3):971-9 [16002463.001]
  • [Cites] Lab Invest. 2005 Dec;85(12):1544-54 [16170336.001]
  • [Cites] J Cell Sci. 2005 Dec 15;118(Pt 24):5811-23 [16317043.001]
  • [Cites] Dev Genes Evol. 2006 Jan;216(1):10-8 [16220264.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1181-6 [16161041.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] J Comp Neurol. 2006 Mar 10;495(2):202-12 [16435287.001]
  • [Cites] J Med Chem. 2006 Feb 9;49(3):1006-15 [16451066.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] Lab Invest. 2006 Jul;86(7):645-53 [16619002.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6589-97 [16818631.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6209-22 [16880530.001]
  • [Cites] Br J Haematol. 2006 Oct;135(1):26-32 [16939498.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2407-15 [16763206.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2796-803 [16825495.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):839-46 [17094947.001]
  • [Cites] Genes Cells. 2006 Dec;11(12):1405-17 [17121547.001]
  • [Cites] World J Gastroenterol. 2006 Nov 28;12(44):7104-12 [17131471.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):859-69 [16878150.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):813-21 [16909118.001]
  • [Cites] FEBS Lett. 2007 Feb 20;581(4):727-34 [17274988.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Cell. 2007 Mar 9;128(5):961-75 [17350579.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2950-4 [17086210.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] J Exp Zool B Mol Dev Evol. 2007 May 15;308(3):269-82 [17285636.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403 [17490616.001]
  • [Cites] Differentiation. 2007 Jun;75(5):418-26 [17286600.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):39-51 [17611206.001]
  • [Cites] J Mol Med (Berl). 2007 Aug;85(8):863-75 [17318615.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2550-8 [19244133.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2776-90 [18845790.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1621-30 [17416736.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3265-8 [10556217.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3614-7 [10610119.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5600-5 [10681541.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):781-9 [10702393.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 21;270(3):936-41 [10772929.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13564-70 [10788472.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Blood. 2000 May 15;95(10):3204-7 [10807789.001]
  • [Cites] Dev Growth Differ. 2000 Apr;42(2):113-9 [10830434.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9526-31 [11121404.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2194-9 [11280786.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2319-33 [11304786.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):419-26 [11310834.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2185-93 [11395396.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Genes Cells. 2001 Jun;6(6):531-44 [11442633.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1209-16 [11493472.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6517-23 [11522649.001]
  • [Cites] Development. 2001 Sep;128(17):3331-8 [11546749.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Cell. 2001 Nov 2;107(3):387-98 [11701128.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Mech Dev. 2002 Jan;110(1-2):85-96 [11744371.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):466-74 [11751994.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1559-66 [11888936.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1487-94 [11943732.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4540-6 [12036886.001]
  • [Cites] Cell. 2002 May 31;109(5):639-49 [12062106.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22231-9 [11919185.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5823-34 [12185581.001]
  • [Cites] J Biochem. 2002 Sep;132(3):359-71 [12204104.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Histopathology. 2002 Nov;41(5):461-7 [12405914.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):517-27 [12555065.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Exp Hematol. 2003 Mar;31(3):226-33 [12644020.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):98-105 [12661011.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2213-20 [12796388.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):427-32 [12800156.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30028-36 [12748172.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1723-33 [19170230.001]
  • [Cites] Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83 [18788887.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):187-90 [12939746.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1255-65 [13679433.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3692-9 [14506160.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):507-12 [14523446.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):512-6 [14523447.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1464-71 [14563642.001]
  • [Cites] Development. 2004 Feb;131(4):743-54 [14757637.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1682-8 [15117990.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4622-9 [14962911.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] J Cell Sci. 2004 Jul 1;117(Pt 15):3319-29 [15226403.001]
  • [Cites] Nature. 2004 Jul 15;430(6997):345-50 [15208641.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5426-34 [15184887.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6071-82 [15208656.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28683-90 [17681947.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2434-43 [17904822.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1341-8 [17922009.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Neuropsychopharmacology. 2008 Feb;33(3):685-700 [17487225.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3743-50 [18070884.001]
  • [Cites] Annu Rev Physiol. 2008;70:431-57 [17850209.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] J Biochem. 2008 Apr;143(4):441-8 [18024471.001]
  • [Cites] PLoS Genet. 2008 Mar;4(3):e1000026 [18369445.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):428-37 [17938159.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2728-36 [17998938.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1536-9 [18414414.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • [Cites] Nat Med. 2008 Jun;14(6):676-80 [18469826.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] Curr Biol. 2008 Aug 5;18(15):1101-9 [18674914.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8899-907 [18974134.001]
  • [Cites] Neuroreport. 2008 Nov 19;19(17):1733-8 [18849880.001]
  • [Cites] Biochem J. 2008 Dec 1;416(2):153-9 [18990089.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4808-17 [19064740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):361-70 [19131589.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):661-70 [19147828.001]
  • [Cites] Neoplasia. 2009 Feb;11(2):145-56 [19177199.001]
  • [Cites] Eur J Neurosci. 2009 Jan;29(2):275-86 [19200234.001]
  • (PMID = 19459784.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 237
  • [Other-IDs] NLM/ PMC2708929
  •  go-up   go-down


Advertisement
4. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res; 2005 Nov 15;65(22):10199-207
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of the PIK3CA gene in anaplastic thyroid cancer.
  • Recently, it has been reported that somatic mutations within the PI3K catalytic subunit, PIK3CA, are common (25-40%) among colorectal, gastric, breast, ovarian cancers, and high-grade brain tumors.
  • In this study, 13 thyroid cancer cell lines, 80 well-differentiated thyroid carcinomas of follicular (WDFC) and papillary (WDPC) type, and 70 anaplastic thyroid carcinomas (ATC) were investigated, by PCR-direct sequencing, for activating PIK3CA mutations at exons 9 and 20.
  • In 18 of the 20 ATC cases showing coexisting differentiated carcinoma, mutations, when present, were restricted to the ATC component and located primarily within the kinase domain.
  • [MeSH-major] Carcinoma / genetics. Mutation, Missense. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / enzymology. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Amino Acid Substitution. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Growth Processes / genetics. Cell Line, Tumor. Enzyme Activation. Genes, p53 / genetics. Genes, ras / genetics. Humans. Oncogene Protein v-akt / metabolism. Proto-Oncogene Proteins B-raf / genetics


5. Kościuch J, Zielonka TM, Ziółkowski B, Domagała-Kulawik J, Bogacka-Zatorska E, Chazan R: [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago]. Pneumonol Alergol Pol; 2006;74(1):129-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago].
  • We describe a case of two simultaneous malignancies--anaplastic gastric carcinoma with pleural metastases and left breast carcinoma.
  • Her parents died from malignancies--mother from gastric cancer and father from pulmonary carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / secondary. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175993.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Hombach-Klonisch S, Bialek J, Trojanowicz B, Weber E, Holzhausen HJ, Silvertown JD, Summerlee AJ, Dralle H, Hoang-Vu C, Klonisch T: Relaxin enhances the oncogenic potential of human thyroid carcinoma cells. Am J Pathol; 2006 Aug;169(2):617-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.
  • The role of members of the insulin-like superfamily in human thyroid carcinoma is primarily unknown.
  • Here we demonstrate the presence of RLN2 relaxin and relaxin receptor LGR7 in human papillary, follicular, and undifferentiated anaplastic thyroid carcinoma suggesting a specific involvement of relaxin-LGR7 signaling in thyroid carcinoma.
  • Stable transfectants of the LGR7-positive human follicular thyroid carcinoma cell lines FTC-133 and FTC-238 that secrete bioactive proRLN2 revealed this hormone to act as a multifunctional endocrine factor in thyroid carcinoma cells.
  • Although RLN2 did not act as a mitogen, it acted as an autocrine/paracrine factor and significantly increased anchorage-independent growth and thyroid carcinoma cell motility and invasiveness through elastin matrices.
  • We found the intracellular distribution of procath-L specifically altered in RLN2 transfectants, providing first evidence for selective actions of relaxin on the powerful elastinolytic cath-L production, storage, and secretion in thyroid carcinoma cells.
  • Thus, relaxin enhances the oncogenic potential and acts as novel endocrine modulator of invasiveness in human thyroid carcinoma cells.
  • [MeSH-major] Carcinoma / pathology. Relaxin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - RXFP1 receptor - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):787-95 [10762753.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):489-99 [15668295.001]
  • [Cites] Neuroscience. 2000;100(3):663-75 [11098128.001]
  • [Cites] Wound Repair Regen. 2000 Sep-Oct;8(5):361-70 [11186125.001]
  • [Cites] Thyroid. 2000 Dec;10(12):1061-9 [11201850.001]
  • [Cites] Regul Pept. 2001 Mar 2;97(2-3):139-46 [11164949.001]
  • [Cites] J Exp Med. 2001 Apr 16;193(8):881-92 [11304549.001]
  • [Cites] Cancer Gene Ther. 2001 Jul;8(7):522-8 [11498774.001]
  • [Cites] Mol Hum Reprod. 2001 Sep;7(9):799-809 [11517286.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7526-33 [11567042.001]
  • [Cites] FASEB J. 2001 Oct;15(12):2187-95 [11641245.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):15-21 [11790528.001]
  • [Cites] Science. 2002 Jan 25;295(5555):671-4 [11809971.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Mol Hum Reprod. 2002 Sep;8(9):789-96 [12200455.001]
  • [Cites] Trends Endocrinol Metab. 2002 Oct;13(8):343-8 [12217491.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Dec;227(11):1047-53 [12486216.001]
  • [Cites] Mol Cell Neurosci. 2003 Feb;22(2):146-61 [12676526.001]
  • [Cites] Int J Oncol. 2003 May;22(5):993-1001 [12684664.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3683-91 [12865351.001]
  • [Cites] J Clin Invest. 2003 Aug;112(4):517-26 [12925692.001]
  • [Cites] Biochemistry (Mosc). 2003 Jul;68(7):711-7 [12946252.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):513-9 [14520686.001]
  • [Cites] Mol Endocrinol. 2003 Dec;17(12):2639-46 [12933905.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):324-34 [14715868.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):91-106 [15168727.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36761-70 [15192101.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4712-20 [15256493.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(2):157-66 [15377840.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand C. 1984 Apr;92(2):107-12 [6203330.001]
  • [Cites] Annu Rev Biochem. 1986;55:167-93 [2943218.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5 [1692625.001]
  • [Cites] Anticancer Res. 1992 Jan-Feb;12(1):235-40 [1567172.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):639-43 [1320450.001]
  • [Cites] Mol Endocrinol. 1992 Sep;6(9):1441-50 [1435788.001]
  • [Cites] Life Sci. 1993;52(12):1055-61 [8445994.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1991-6 [8364879.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26668-72 [8253799.001]
  • [Cites] J Mol Endocrinol. 1994 Jun;12(3):351-64 [7916973.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3599-608 [7641679.001]
  • [Cites] Surgery. 1995 Dec;118(6):1036-40 [7491520.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):3009-13 [8770925.001]
  • [Cites] J Biol Chem. 1996 Nov 1;271(44):27936-41 [8910395.001]
  • [Cites] Annu Rev Physiol. 1997;59:63-88 [9074757.001]
  • [Cites] Cell Tissue Res. 1997 Jul;289(1):109-17 [9182605.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3383-8 [9329373.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4713-20 [9348198.001]
  • [Cites] J Endocrinol. 1960 Nov;21:241-6 [13736410.001]
  • [Cites] J Endocrinol. 1963 Jun;26:331-8 [13944118.001]
  • [Cites] Endocrinology. 1963 Feb;72:337-40 [14015096.001]
  • [Cites] Nat Med. 2005 Feb;11(2):206-13 [15665831.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:449-61 [15956746.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1041:462-9 [15956747.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):307-15 [16010410.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):482-7 [10931446.001]
  • (PMID = 16877360.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RLN2 protein, human; 0 / RNA, Messenger; 0 / RXFP1 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Peptide; 9002-69-1 / Relaxin; 9007-58-3 / Elastin; EC 3.4.- / Cathepsins
  • [Other-IDs] NLM/ PMC1698779
  •  go-up   go-down


7. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • We describe two cases of lymphoid malignancies predominantly involving the breast, both presenting diagnostic dilemmas.
  • The first case, ALK-negative anaplastic large-cell lymphoma involving a seroma associated with a breast implant, is an emerging clinicopathologic entity.
  • Anaplastic large-cell lymphoma has been identified in association with breast implants and seroma formation relatively recently.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


8. Kaya H, Güllüoglu B, Aribal E: Myoepithelial differentiation in breast carcinoma. Tumori; 2008 Jan-Feb;94(1):116-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial differentiation in breast carcinoma.
  • BACKGROUND: The aim of presenting this work is to describe a matrix producing carcinoma with anaplastic myoepithelial cell foci, with the coexistence of in situ myoepithelial carcinoma which originated from a sclerosing adenosis.
  • CASE REPORT: A 51-year-old perimenopausal woman presented with a hard irregular lump in her left breast.
  • The tumor was composed of a sclerosed fibroadenoma and preexisting sclerosing adenosis with poorly differentiated overt carcinoma within the cartilaginous matrix.
  • There were foci of ordinary, intermediate-grade carcinoma in situ and myoepithelial carcinoma in situ.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroadenoma / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Carcinoma in Situ / pathology. Cell Differentiation. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Middle Aged


9. Mobini N: Acantholytic anaplastic Paget's disease. J Cutan Pathol; 2009 Mar;36(3):374-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acantholytic anaplastic Paget's disease.
  • 'Anaplastic' variant of this disease is a less-recognized subset that may pose as a diagnostic challenge and pitfall.
  • A high-grade ductal carcinoma in situ in the underlying breast was ultimately found in both cases.
  • Anaplastic PD is a rare variant of this disease that histologically mimics Bowen's disease with an associated prominent superficial acantholysis.
  • A high index of suspicion along with a complete immunohistochemical panel should be considered in evaluating any Bowenoid neoplasm of the breast skin, particularly in superficial skin shave biopsies along with negative imaging studies and no palpable mass clinically.
  • [MeSH-minor] Aged, 80 and over. Bowen's Disease / metabolism. Bowen's Disease / pathology. Carrier Proteins / metabolism. Diagnosis, Differential. Female. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Nipples / metabolism. Nipples / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220635.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mucins; 0 / PIP protein, human
  •  go-up   go-down


10. Iyengar P, Reid-Nicholson M, Moreira AL: Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma. Diagn Cytopathol; 2006 Apr;34(4):298-302
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma.
  • Anaplastic large-cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults.
  • It has been described in numerous sites; however, the breast is one of the least common locations.
  • We herein report a case of ALCL arising in the breast of a 36-yr-old pregnant woman.
  • We would like to highlight the cytologic and histologic features of ALCL, as this case was initially misdiagnosed as a ductal carcinoma.
  • Differential diagnosis with other tumors is also discussed.
  • This case serves to emphasize the importance of the triple test, and the need for correlation of fine-needle aspiration findings with core biopsy findings in breast tumor management.
  • [MeSH-major] Breast / pathology. Carcinoma, Ductal, Breast / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pregnancy


11. Noh TW, Soung YH, Kim HI, Gil HJ, Kim JM, Lee EJ, Chung J: Effect of {beta}4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma. Anticancer Res; 2010 Nov;30(11):4485-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of {beta}4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma.
  • This study reports that α6β4 expression is selectively up-regulated in anaplastic thyroid cancer (ATC) cells, the most malignant subtype of human thyroid cancer.
  • [MeSH-major] Carcinoma / genetics. Cell Movement. Cell Proliferation. Integrin alpha6beta4 / genetics. RNA Interference. RNA, Small Interfering / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Breast Neoplasms / prevention & control. Cell Adhesion. Cell Line, Tumor. Female. Flow Cytometry. Humans. Mice. Mice, Nude. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Rate. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115897.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Integrin alpha6beta4; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


12. Daneshbod Y, Oryan A, Khojasteh HN, Rasekhi A, Ahmadi N, Mohammadianpanah M: Primary ALK-positive anaplastic large cell lymphoma of the breast: a case report and review of the literature. J Pediatr Hematol Oncol; 2010 Mar;32(2):e75-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for alk-positive anaplastic large cell lymphoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ALK-positive anaplastic large cell lymphoma of the breast: a case report and review of the literature.
  • BACKGROUND: Non-Hodgkin lymphomas of the breast are uncommon, which represent less than 1% of all breast malignancies and predominantly are of B-cell origin.
  • OBSERVATION: In this report, a rare case of anaplastic lymphoma kinase (ALK)-positive anaplastic large T-cell lymphoma in the breast of a 16-year-old female without breast implant is described.
  • The patient presented with a 3-month history of progressive right breast swelling and erythema.
  • Clinically, inflammatory breast carcinoma was highly suspected.
  • A tru-cut needle biopsy of the right breast demonstrated infiltration of tumoral cells around the breast lobules and soft tissue and also in angiolymphatic spaces.
  • The immunohistochemical profile showed positivity for CD30 and ALK and confirmed the diagnosis of ALK-positive anaplastic large T-cell lymphoma of the breast.
  • CONCLUSION: Anaplastic large T-cell lymphoma of the breast is rare, and can clinically mimic inflammatory breast carcinoma in adolescence.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168249.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 33
  •  go-up   go-down


13. Fritzsche FR, Pahl S, Petersen I, Burkhardt M, Dankof A, Dietel M, Kristiansen G: Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer--a case report. Virchows Arch; 2006 Nov;449(5):561-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer--a case report.
  • Primary, as well as secondary, lymphomas of the breast are rare diseases and might, in some cases, be misdiagnosed as breast cancer on routine hematoxylin/eosin stainings.
  • We report a case of an anaplastic large cell lymphoma in a 72-year-old woman with a history of breast cancer treated with breast-ablative surgery and a subsequent silicon implant 32 years ago.
  • On conventional histology, the tumor cells were mimicking poorly differentiated invasive ductal carcinoma with a prominent leukocytic infiltrate.
  • The immunoprofile of the tumor showed negativity for cytokeratins and led to the diagnosis of a CD30-positive anaplastic large cell lymphoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Aged. Antigens, CD30 / analysis. Breast Implants. Female. Humans. Immunohistochemistry


14. Kriuchkov AN, Freĭnd GG: [Neoangiogenesis and density of microvessels in breast carcinoma tissue]. Arkh Patol; 2008 Jan-Feb;70(1):62-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoangiogenesis and density of microvessels in breast carcinoma tissue].
  • The morphology of neoangiogenesis in breast carcinoma tissue is considered as a relationship between the density of the tumor vascular bed and different indices (age, histological type of a tumor, stage of the disease, tumor anaplastic proliferative activity, fibrosis degree, stromal cellularity, and parenchymal destructive changes).
  • [MeSH-major] Breast Neoplasms / blood supply. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18368815.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 50
  •  go-up   go-down


15. Kelten C, Kabukcu S, Sen N, Teke Z, Yaren A, Erdem E, Duzcan E: Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma. Arch Gynecol Obstet; 2009 Jul;280(1):149-52
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma.
  • Non-Hodgkin lymphoma of the breast is a rare malignancy and present with almost equal frequency either as a primary or a secondary disease.
  • Survival is poor in most cases of secondary breast lymphoma because of their advanced stage.
  • We report a 35-year-old woman presenting with dyspnea as well as swelling, tenderness, and ruddiness in the left breast with non-cyclic pain for several months and maculopapular skin eruption in the same breast.
  • Radiologic evaluations (bilateral mammaograpy and ultrasonography) showed skin thickening in the left breast, asymmetrical densities in both breasts, and confirmed lymphadenopathies in the axillary regions.
  • Excisional biopsies were performed to the left axillary lymph nodes and the breast skin eruptions.
  • The histologic and immunohistochemical features were diagnosed as an ALK (-) anaplastic large cell lymphoma.
  • Thirty months after the diagnosis, the patient is still alive with disease.
  • Because of the presence of systemic symptoms such as skin involvement and generalized lymphadenopathies (mediastinal, axillary or cervical), T cell lymphoma cases with breast involvement could mimic the clinical presentation of inflammatory breast carcinoma.
  • Pathologic examination is needed for the correct diagnosis.
  • [MeSH-major] Breast Neoplasms / secondary. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Mammography. Neoplasm Staging. Tomography, X-Ray Computed


16. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S: Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch; 2005 Jan;446(1):10-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.
  • Medullary carcinoma (MC) of the breast is characterized by large anaplastic cells and infiltration by benign lymphocytes.
  • Patients with this pattern of breast carcinoma are considered to have a better prognosis than those with other histological subtypes.
  • We reviewed cases of primary breast carcinoma that were surgically resected between 1990 and 2004.
  • Of these, 13 cases of medullary carcinoma of the breast with lymphocyte infiltration were reported.
  • Furthermore, more CD8-positive than CD4-positive T-cell lymphocytes were present within the tumor cell nests in MC, as opposed to the proportion in usual ductal carcinoma.
  • [MeSH-major] Breast Neoplasms / immunology. Carcinoma, Medullary / immunology. Lymphocytes, Tumor-Infiltrating / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660281.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD8; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


17. Kurokawa K, Mouri Y, Asano A, Kamei K, Iwata Y, Isogai M, Saga S, Ichihara S: Pleomorphic carcinoma with osteoclastic giant cells of the breast: immunohistochemical differentiation between coexisting neoplastic and reactive giant cells. Pathol Int; 2009 Feb;59(2):91-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic carcinoma with osteoclastic giant cells of the breast: immunohistochemical differentiation between coexisting neoplastic and reactive giant cells.
  • Herein is described a unique case of breast carcinoma with two different types of giant cells noted in both cytological and histological specimens.
  • A 51-year-old Japanese woman noticed a hard mass in the upper outer quadrant of her left breast.
  • Aspiration cytology exhibited numerous anaplastic giant cells; the cytological diagnosis was high-grade ductal carcinoma, although a few osteoclastic giant cells were also observed.
  • Histologically, approximately 90% of the tumor was composed of giant cells; conventional invasive ductal carcinoma and ductal carcinoma in situ were found focally at the periphery of the tumor.
  • The main part of the tumor contained both anaplastic, neoplastic giant cells and non-neoplastic, osteoclastic giant cells that were distinguishable from nuclear atypism.
  • Based on the latest World Health Organization classification, the diagnosis was pleomorphic carcinoma with osteoclastic giant cells.
  • To the authors' knowledge there has been no previous report on this subject except for a single case mentioned in Rosen's Breast Pathology.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Giant Cell / diagnosis. Giant Cells / pathology. Neoplasms, Complex and Mixed / diagnosis. Osteoclasts / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Mastectomy, Simple. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154262.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Gol Choe J, Kim YR, Kim KN, Choo HJ, Shin JH, Lee YJ, Chung JK, Kim MK: Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. Nucl Med Commun; 2005 Dec;26(12):1155-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
  • NIS gene transfection, a gene-therapy modality, has been introduced in many types of cancer, such as prostate cancer and breast cancer, and has demonstrated a high potential for the treatment of non-thyroidal cancers.
  • AIM: To investigate the pattern of NIS gene expression and provide evidence of its beneficial effects in human anaplastic cancer ARO cells by using a radioactive complementary DNA (cDNA) microarray.
  • Moreover, NIS gene transfection into an anaplastic thyroid cancer cell line affected the expression of the protein tyrosine phosphatase (PTP) family and Ras oncogene family, including Ras, Rac and Rab.
  • [MeSH-major] Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Symporters / biosynthesis. Symporters / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264365.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Symporters; 0 / sodium-iodide symporter
  •  go-up   go-down


19. Rossbach HC, Baschinsky D, Wynn T, Obzut D, Sutcliffe M, Tebbi C: Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation. Pediatr Blood Cancer; 2008 Mar;50(3):681-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation.
  • LFS predisposes to the development of leukemia, sarcomas, adrenocortical and breast carcinomas, brain tumors and, questionably, NB.
  • [MeSH-minor] Amino Acid Substitution. Aneuploidy. Brain Neoplasms / genetics. Breast Neoplasms / genetics. Carcinoma / genetics. Choroid Plexus Neoplasms / genetics. Female. Glioblastoma / genetics. Humans. Infant. Loss of Heterozygosity. Male. Pedigree

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427234.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Khanafshar E, Phillipson J, Schammel DP, Minobe L, Cymerman J, Weidner N: Inflammatory myofibroblastic tumor of the breast. Ann Diagn Pathol; 2005 Jun;9(3):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the breast.
  • No lesions were positive for anaplastic lymphoma kinase-1, desmin, S-100, CD34, CD21, or CD35.
  • In each case, a diagnosis of inflammatory myofibroblastic tumor was made (aka, inflammatory pseudotumor).
  • We report these patients to emphasize the diagnostic features of inflammatory myofibroblastic tumor of the breast and discuss how they can be distinguished from other spindle-cell breast lesions with which they can be confused, especially spindle-cell carcinoma.
  • [MeSH-major] Breast Diseases / pathology. Granuloma, Plasma Cell / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers / metabolism. Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944952.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 26
  •  go-up   go-down


21. Kiyamova R, Kostianets O, Malyuchik S, Filonenko V, Usenko V, Gurtovyy V, Khozayenko Y, Antonuk S, Old L, Gout I: Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach. Mol Biotechnol; 2010 Oct;46(2):105-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach.
  • Medullary breast carcinoma (MBC) is a relatively rare malignancy with heavy lymphocytic infiltration that despite cytologically anaplastic features and high mitotic index has more favorable prognosis than other types of breast cancer.
  • [MeSH-major] Antigens, Neoplasm / genetics. Breast Neoplasms / genetics. Carcinoma, Medullary / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20440581.001).
  • [ISSN] 1559-0305
  • [Journal-full-title] Molecular biotechnology
  • [ISO-abbreviation] Mol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA, Complementary; 0 / Immune Sera
  •  go-up   go-down


22. Di Saverio S, Gutierrez J, Avisar E: A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat; 2008 Oct;111(3):541-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
  • BACKGROUND: Pure mucinous breast carcinoma (PMBC) is a rare histologic type of mammary neoplasm.
  • It has been associated with a better short-term prognosis than infiltrating ductal carcinoma (IDC) but identical long-term survival curves have been reported.
  • The prognostic significance of gender, race, laterality, age at diagnosis, T and N status, estrogen and progesterone receptors and administration of radiation therapy was calculated by univariate and multivariate analysis.
  • The median age at diagnosis was 71 years (Range 25-85).
  • Fifty three percent of the tumors were well differentiated, 38% were moderately differentiated and the remaining 9% were poorly differentiated or anaplastic.
  • Kaplan Meier survival curves revealed a 5 years. breast cancer specific survival rate of 94%.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Breast Neoplasms / epidemiology. Carcinoma, Ductal, Breast / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026874.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Cossu A, Budroni M, Capobianco G, Pirino D, Palmieri G, Dessole S, Tanda F, Cesaraccio R, Cherchi PL: Epidemiology of malignant breast tumors in the province of Sassari (Sardinia, Italy) in the period 1992-2002. Eur J Gynaecol Oncol; 2005;26(5):505-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of malignant breast tumors in the province of Sassari (Sardinia, Italy) in the period 1992-2002.
  • The aim of this study was to evaluate the incidence of malignant breast tumors in the Province of Sassari, Sardinia (Italy) in the period 1992-2002 and to report the variations in comparison to the 1974-1985 period.
  • The analysis of our data showed that the overall number of malignant breast tumors was more than doubled from 1,139 cases in the period 1974-1985 to the 2,735 cases in the period 1992-2002, and the mean rate/100,000 changed from 43.4 to 106.0.
  • The incidence in the age classes 45-64 years, which were at enhanced risk for breast cancer, was globally increased, changing from 143.6/100,000 to 198.7/100,000.
  • The analysis of the histotypes showed a relative reduction of ductal carcinoma in the period 1992-2002 in comparison to the previous period 1974-1985 (65.2% vs 82.0%) whereas the incidence of anaplastic forms increased in advanced ages of life.
  • In conclusion, the worrying data of the strong reduction of T0 cases, the increased age of first diagnosis and the advanced forms with positive nodal metastases showed that the prevention program has not been yet well organized.
  • [MeSH-major] Breast Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / etiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / etiology. Carcinoma, Lobular / pathology. Female. Humans. Incidence. Italy / epidemiology. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285566.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Gogo-Abite M, Nwosu SO: Histopathological characteristics of female breast carcinomas seen at the University of Port Harcourt Teaching Hospital, Port Harcourt Nigeria. Niger J Med; 2005 Jan-Mar;14(1):72-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological characteristics of female breast carcinomas seen at the University of Port Harcourt Teaching Hospital, Port Harcourt Nigeria.
  • BACKGROUND: Breast carcinoma is an unpredictable disease in the sense that some patients may present with relatively early disease and die of widespread metastases within six months to one year, while others present with fairy advanced disease and yet survive longer.
  • The aim of this study was to characterize breast carcinomas into prognostic groups using histological features.
  • METHODOLOGY: A total of 269 breast carcinomas in females received during a five-year period (January 1991 to December 1995 inclusive) were analyzed.
  • Archive records (request forms and microscopic slides) of all breast malignancies diagnosed in the department of Anatomical Pathology of University of Port Harcourt Teaching Hospital were retrieved and evaluated with respect to histological type, histological grades, and mononuclear cell infiltration within the primary tumour.
  • The modified Bloom-Richardson system of microscopic grading of breast carcinoma was used.
  • Forty-nine percent of carcinomas show poorly differentiated or anaplastic nuclei.
  • The majority of the breast carcinomas in this study, 58%, show scanty or absent mononuclear infiltration.
  • CONCLUSION: The majority of breast carcinomas in this study are poorly differentiated invasive ductal carcinoma, "not otherwise specified" which exhibit high proliferation ratio and are associated with poor host cellular immune reaction.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Carcinoma / epidemiology. Carcinoma / pathology. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832647.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. De Padua M, Kaul S, Sarin R, Kaul S, Das PK: Primary lymphoma of the breast: a clinicopathological study. Indian J Pathol Microbiol; 2007 Oct;50(4):722-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the breast: a clinicopathological study.
  • 3 cases of primary non Hodgkins lymphoma of the breast are described, seen over a period of 2 years among 199 cases of breast malignancies.
  • Application of immunohistochemistry greatly aids in differentiating lymphoma from anaplastic carcinoma, with which it can easily be confused.
  • Preoperative diagnosis on a trucut biopsy is an ideal diagnostic method since diagnosis on fine needle aspiration cytology or frozen section may not be possible.
  • Primary breast lymphoma is a rare disease with reported incidence of 0.04-0.53% of all breast malignancies in most series.
  • Accurate diagnosis is essential, so that appropriate treatment may be applied.
  • [MeSH-major] Breast Neoplasms / pathology. Hodgkin Disease / complications. Lymphoma / diagnosis. Lymphoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Carcinoma / diagnosis. Carcinoma / pathology. Cyclophosphamide. Diagnosis, Differential. Doxorubicin. Female. Humans. Middle Aged. Prednisolone. Vincristine

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306536.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


26. Kapucuoglu N, Percinel S, Ventura T, Lang R, Al-Daraji W, Eusebi V: Dendritic cell sarcomas/tumours of the breast: report of two cases. Virchows Arch; 2009 Mar;454(3):333-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell sarcomas/tumours of the breast: report of two cases.
  • We present two cases of FDCS/T and IDCS/T of the breast.
  • The FDCS/T case (case 1) presented in a 31-year-old woman and the IDCS/T case (case 2) in a 67-year-old woman who both showed a firm lump in the left breast.
  • The FDCS/T lesion superficially appeared as an anaplastic carcinoma and the IDCS/T was reminiscent of a spindle cell sarcomatoid carcinoma.
  • In breast, an unusual keratin negative tumour composed predominantly of spindle cells arranged in fascicles, storiform pattern or whorls with a lymphoid rich stroma should raise suspicion for FDCS/Ts or IDCS/Ts.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Dendritic Cell Sarcoma, Follicular / metabolism. Dendritic Cell Sarcoma, Follicular / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189126.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / Receptors, Complement 3d; 0 / S100 Proteins; 0 / Vimentin; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


27. Angeles-Angeles A, Chable-Montero F, Martinez-Benitez B, Albores-Saavedra J: Unusual metastases of papillary thyroid carcinoma: report of 2 cases. Ann Diagn Pathol; 2009 Jun;13(3):189-96
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual metastases of papillary thyroid carcinoma: report of 2 cases.
  • We present 2 cases of papillary thyroid carcinoma (PTC) with conventional morphology that metastasized to unusual sites.
  • The second case was that of a 58-year-old woman with a PTC with initial metastases in cervical lymph nodes; subsequently, the tumor spread to axillary lymph nodes and finally to the breast.
  • Transformation to anaplastic spindle and giant cell carcinoma within the breast metastasis occurred 20 years after the primary thyroid tumor had been diagnosed and surgically treated.
  • The metastatic anaplastic spindle and giant cell carcinoma contained rhabdoid inclusions further complicating identification.
  • To the best of our knowledge, only 3 cases of PTC metastatic to the breast have been reported, none of them with anaplastic transformation.
  • Brief comments about the differential diagnosis are included.
  • [MeSH-major] Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Pancreatic Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433299.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Koukouras D, Spyropoulos C, Siasos N, Sdralis E, Tzorakoleftherakis E: Is sentinel node biopsy reliable in large breast tumors? Eur J Gynaecol Oncol; 2010;31(1):80-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is sentinel node biopsy reliable in large breast tumors?
  • PURPOSE: The value of sentinel lymph node biopsy (SNB) in patients with larger breast tumors (diameter > 3 cm) has been questioned due to high false-negative rates reported from initial studies.
  • METHODS: During a 6-year period (2001-2007), 84 women with mean age 51.7 +/- 11.6 years diagnosed with a breast tumor larger than 3 cm in diameter on pathological analysis were retrospectively identified from the database of our institution.
  • RESULTS: Breast surgery consisted of mastectomy in 62 patients (73.8%) and partial mastectomy in 22 patients (26.2%).
  • There were 69 invasive ductal cancers (82.1%), 14 lobular cancers (16.6%) and one case of anaplastic carcinoma (1.3%).
  • CONCLUSIONS: The present study indicates that sentinel node biopsy is feasible in patients with larger breast tumors (max. diameter > 3 cm), with comparable false-negative and sentinel detection rates (14.3% and 96.4%, respectively).
  • [MeSH-major] Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349786.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Perez-Pinera P, Garcia-Suarez O, Menendez-Rodriguez P, Mortimer J, Chang Y, Astudillo A, Deuel TF: The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun; 2007 Oct 12;362(1):5-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer.
  • Increasing evidence suggests mutations in human breast cancer cells that induce inappropriate expression of the 18-kDa cytokine pleiotrophin (PTN, Ptn) initiate progression of breast cancers to a more malignant phenotype.
  • Recently, PTN was found to activate anaplastic lymphoma kinase (ALK) through the PTN/RPTPbeta/zeta signaling pathway; this discovery potentially is very important, since constitutive ALK activity of nucleophosmin (NPM)-ALK fusion protein is causative of anaplastic large cell lymphomas, and, activated ALK is found in other malignant cancers.
  • Recently ALK was identified in each of 63 human breast cancers from 22 subjects.
  • We now demonstrate that RPTPbeta/zeta is expressed in each of these same 63 human breast cancers that previously were found to express ALK and in 10 additional samples of human breast cancer.
  • RPTPbeta/zeta furthermore was localized not only in its normal association with the cell membrane but also scattered in cytoplasm and in nuclei in different breast cancer cells and, in the case of infiltrating ductal carcinomas, the distribution of RPTPbeta/zeta changes as the breast cancer become more malignant.
  • The data suggest that the PTN/RPTPbeta/zeta signaling pathway may be constitutively activated and potentially function to constitutively activate ALK in human breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2006 Feb;208(2):231-8 [16441567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12407-12 [16116087.001]
  • [Cites] FEBS Lett. 2006 Jul 24;580(17):4051-6 [16814777.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403 [17490616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6593-8 [11381105.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):162-71 [11795867.001]
  • [Cites] J Immunoassay Immunochem. 2002;23(1):33-48 [11848100.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):823-7 [11895915.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):858-63 [11953815.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2582-7 [1733956.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25889-97 [1464602.001]
  • [Cites] Cancer. 1994 Sep 1;74(5):1584-90 [7520350.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):309-14 [7533562.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16733-6 [9201975.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):537-43 [9389569.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1468-73 [9776412.001]
  • [Cites] Prostate. 1999 Feb 1;38(2):126-36 [9973098.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12474-9 [10212223.001]
  • [Cites] J Cutan Pathol. 2005 Feb;32(2):125-30 [15606670.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):637-43; discussion 644-5 [15684595.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 8;332(3):664-9 [15925565.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 16;335(1):232-9 [16105548.001]
  • [Cites] Neurosci Lett. 2006 May 15;399(1-2):33-8 [16513268.001]
  • (PMID = 17706593.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084400-06; United States / NCI NIH HHS / CA / R01 CA084400; United States / NIDDK NIH HHS / DK / T32 DK007022; United States / NCI NIH HHS / CA / R01 CA084400-06
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin; 137497-38-2 / midkine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / PTPRZ1 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  • [Other-IDs] NLM/ NIHMS30386; NLM/ PMC2084077
  •  go-up   go-down


30. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z: Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res; 2009 Sep;7(9):1466-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
  • The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene has been identified as an oncogene in a subset of non-small cell lung cancers (NSCLC).
  • This approach led to the detection of EML4-ALK fusion in breast and colorectal carcinomas in addition to NSCLC.
  • Screening of a large collection of patient tumor samples showed the presence of EML4-ALK fusion in 2.4% of breast (5 of 209), 2.4% of colorectal (2 of 83), and in 11.3% of NSCLC (12 of 106).
  • A20) and 2 (E20; A20), a novel variant E21; A20 was found in colorectal carcinoma.
  • The presence of an EML-ALK rearrangement was verified by identifying genomic fusion points in tumor samples representative of breast, colon, and NSCLC.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Colorectal Neoplasms / genetics. Exons. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737969.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Small Interfering
  •  go-up   go-down


31. Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR: YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun; 2010 Jul 30;398(3):482-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis.
  • YB-1 is linked to poor prognosis in breast carcinoma and is a strong predictor of relapse and disease-specific survival.
  • Non-invasive MCF-7 breast adenocarcinoma cells were transfected with YB-1/EGFP.
  • MCF-7 cells expressing a twofold increase in YB-1 formed highly anaplastic tumors with local invasion, pulmonary metastases and high lethality.
  • We conclude that YB-1 contributes to the development of an invasive, metastatic breast carcinoma phenotype by enhanced presentation of MT1-MMP at the sites of cellular invasion.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] EMBO J. 2001 Oct 1;20(19):5491-502 [11574481.001]
  • [Cites] RNA Biol. 2009 Jan-Mar;6(1):59-64 [19098458.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18241-8 [12604611.001]
  • [Cites] Bioessays. 2003 Jul;25(7):691-8 [12815724.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] J Cell Sci. 2003 Oct 1;116(Pt 19):3905-16 [12915589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7322-6 [3174636.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15074-83 [8663054.001]
  • [Cites] Nat Med. 1997 Apr;3(4):447-50 [9095180.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22905-12 [9278454.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32957-65 [9830047.001]
  • [Cites] J Cell Sci. 1999 Oct;112 ( Pt 20):3487-96 [10504297.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7702-11 [15615704.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4078-87 [15899797.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30564-73 [15985431.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4872-9 [16651443.001]
  • [Cites] EMBO J. 2007 Mar 21;26(6):1499-510 [17332756.001]
  • [Cites] BMC Biochem. 2008;9:23 [18793384.001]
  • [Cites] Breast Cancer Res. 2008;10(5):R86 [18925950.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • (PMID = 20599698.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R56 DK039776; United States / NIDDK NIH HHS / DK / DK039776-21; United States / NIDDK NIH HHS / DK / DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776-21; United States / NIDDK NIH HHS / DK / K08 DK059383-05; United States / NIDDK NIH HHS / DK / R01 DK039776; United States / NIDDK NIH HHS / DK / R01-DK39776; United States / NIDDK NIH HHS / DK / KO8-DK59381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS225358; NLM/ PMC2925540
  •  go-up   go-down


32. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M: EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer; 2008 May 6;98(9):1536-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.
  • The EML4-ALK (EML4: echinoderm microtubule-associated-protein-like 4; ALK: anaplastic lymphoma kinase) fusion gene has been identified as an oncogene in non-small-cell lung cancer (NSCLC).
  • This study examined the presence of this fusion transcript in gastrointestinal and breast cancers.
  • We evaluated the expression of the EML4-ALK transcript in 104 lung cancer cases and in 645 gastrointestinal and breast cancer samples.
  • Only one of the lung cancer samples tested positive for the EML4-ALK fusion transcript, whereas none were detected in 555 gastrointestinal and 90 breast cancer cases.
  • Our data suggest that the EML4-ALK fusion transcript is not present in gastrointestinal or breast cancers and is specific to NSCLC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Gastrointestinal Neoplasms / chemistry. Lung Neoplasms / chemistry. Oncogene Proteins, Fusion / analysis


33. Weed BR, Folpe AL: Cutaneous CD30-positive epithelioid angiosarcoma following breast-conserving therapy and irradiation: a potential diagnostic pitfall. Am J Dermatopathol; 2008 Aug;30(4):370-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD30-positive epithelioid angiosarcoma following breast-conserving therapy and irradiation: a potential diagnostic pitfall.
  • A case of cutaneous epithelioid angiosarcoma with anomalous CD30 expression, occurring after breast-conserving surgery and adjuvant irradiation, is reported.
  • The differential diagnosis of CD30 epithelioid angiosarcoma is discussed.
  • [MeSH-minor] Aged, 80 and over. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / pathology. Radiotherapy, Adjuvant / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645308.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


34. Radulescu RT, Hufnagel C, Luppa P, Hellebrand H, Kuo WL, Rosner MR, Harbeck N, Giersig C, Meindl A, Schmitt M, Weirich G: Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels. Int J Oncol; 2007 Jan;30(1):73-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.
  • We have now determined insulin in extracts of 23 primary breast cancer specimens and of non-neoplastic breast tissues by a chemiluminescent immunoassay.
  • IDE was detected in most insulin-positive grade 3 carcinomas, indicating that it might be dysfunctional in these anaplastic tumors.
  • Moreover, five grade 3 carcinomas and one grade 2 carcinoma displayed a loss of heterozygosity in the 10q chromosomal region harboring the IDE gene, but, despite these alterations, IDE was detected immunohistochemically, indicating a retention of the second allele.
  • Compared to the expression of IDE in 92% of the tumors examined, only 57% of 21 normal breast specimens stained positively for IDE.
  • In contrast to this increase in IDE-positive epithelial cells in breast cancer vs. normal breast, additional immunohistochemical analysis of 17 node-positive breast carcinomas and corresponding tumor-bearing lymph nodes showed that IDE expression decreases from primary tumor to lymph node metastasis.
  • [MeSH-major] Breast / enzymology. Breast Neoplasms / enzymology. Insulin / metabolism. Insulysin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143514.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Insulin; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.4.24.56 / Insulysin
  •  go-up   go-down


35. Kruk-Zagajewska A, Milecki P, Wierzbicka M: [Advances in the diagnosis of unknown primary carcinoma of the neck]. Otolaryngol Pol; 2005;59(1):77-83
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in the diagnosis of unknown primary carcinoma of the neck].
  • The diagnosis of carcinoma of unknown primary is set, when histologically the neck metastases are confirmed but the primary focus is not possible to be found or occurs during the follow-up.
  • The squamous cell carcinoma or anaplastic carcinoma recognized in the neck nodes suggest, that the primary focus is localised in the head and neck region.
  • The knowledge of carcinoma cells spreading paths between particular neck regions is crucial for effective diagnostics of tumor localization in upper aerodigestive tract.
  • In 17 patients the primary localisation was revealed during the follow-up period in: nasopharynx, palatine tonsil, hypopharynx, testis and breast.
  • [MeSH-major] Carcinoma / diagnosis. Head and Neck Neoplasms / diagnosis. Neoplasms, Unknown Primary / diagnosis

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915923.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


36. Benbrahim-Tallaa L, Tokar EJ, Diwan BA, Dill AL, Coppin JF, Waalkes MP: Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect; 2009 Dec;117(12):1847-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype.
  • BACKGROUND: Breast cancer has recently been linked to cadmium exposure.
  • Thus, we studied the effects of chronic exposure to cadmium on the normal human breast epithelial cell line MCF-10A, which is ER-negative but can convert to ER-positive during malignant transformation.
  • Transformant cells were molecularly characterized by protein and transcript analysis of key genes in breast cancer.
  • Inoculation of cadmium-treated cells into mice produced invasive, metastatic anaplastic carcinoma with myoepithelial components.
  • These cadmium-transformed breast epithelial (CTBE) cells displayed characteristics of basal-like breast carcinoma, including ER-alpha negativity and HER2 (human epidermal growth factor receptor 2) negativity, reduced expression of BRCA1 (breast cancer susceptibility gene 1), and increased CK5 (cytokeratin 5) and p63 expression.
  • CK5 and p63, both breast stem cell markers, were prominently overexpressed in CTBE cell mounds, indicative of persistent proliferation.
  • CTBE cells showed global DNA hypomethylation and c-myc and k-ras overexpression, typical in aggressive breast cancers.
  • CONCLUSIONS: Cadmium malignantly transforms normal human breast epithelial cells-through a mechanism not requiring ER-alpha-into a basal-like cancer phenotype.
  • Direct cadmium induction of a malignant phenotype in human breast epithelial cells strongly fortifies a potential role in breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 2000 Apr;14(4):545-53 [10770491.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):711-21 [17464311.001]
  • [Cites] Biol Reprod. 2000 Jul;63(1):259-66 [10859267.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Exp Cell Res. 2003 Jun 10;286(2):355-65 [12749863.001]
  • [Cites] Nat Med. 2003 Aug;9(8):1081-4 [12858169.001]
  • [Cites] Cell Prolif. 2003 Oct;36 Suppl 1:73-84 [14521517.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):107-20 [14643415.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):201-9 [14643421.001]
  • [Cites] Breast Cancer Res Treat. 2004 Apr;84(3):273-88 [15026625.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):358-73 [17717437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5 [18230721.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):108-12 [18227734.001]
  • [Cites] Medicina (Kaunas). 2008;44(6):415-20 [18660635.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6435-41 [18676869.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):27-37 [15082916.001]
  • [Cites] Pathol Oncol Res. 2004;10(2):74-9 [15188022.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4585-92 [15231670.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5792-8 [15122325.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7078-85 [15466203.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16896-901 [8207012.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1993;58:119-237 [8022055.001]
  • [Cites] Sci Total Environ. 1996 Jul 30;186(3):251-6 [8677430.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):907-15 [9772278.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):346-55 [15551354.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Przegl Lek. 2004;61(7):786-8 [15792022.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):369-75 [15816560.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 15;206(3):288-98 [16039940.001]
  • [Cites] Clin Exp Metastasis. 2005;22(3):275-84 [16158255.001]
  • [Cites] Histopathology. 2005 Nov;47(5):458-66 [16241993.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] J Appl Toxicol. 2006 May-Jun;26(3):191-7 [16489580.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):869-73 [16788160.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Oct 1;216(1):20-8 [16716372.001]
  • [Cites] Trends Mol Med. 2006 Nov;12(11):537-44 [17011236.001]
  • [Cites] Stem Cell Rev. 2005;1(3):207-13 [17142857.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4243-52 [17130135.001]
  • [Cites] Neuro Endocrinol Lett. 2006 Dec;27 Suppl 1:36-9 [16804515.001]
  • [CommentIn] Environ Health Perspect. 2009 Dec;117(12):A552 [20049192.001]
  • (PMID = 20049202.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / HHSN261200800001E; United States / PHS HHS / / HHSN261200800001E; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Estrogen Receptor alpha; 0 / Keratin-5; 0 / Membrane Proteins; 00BH33GNGH / Cadmium; EC 1.14.14.1 / Aromatase
  • [Other-IDs] NLM/ PMC2799457
  • [Keywords] NOTNLM ; basal-type / breast cancer / cadmium / estrogen receptor / malignant transformation
  •  go-up   go-down


37. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
  • BACKGROUND: HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab.
  • We wanted to investigate the frequency and clinical significance of HER-2/neu amplification in gastric carcinoma.
  • Sensitivity of a gastric cancer cell line N87 with HER-2/neu amplification to trastuzumab was studied by a cell viability assay and compared with that of a HER-2 amplified breast cancer cell line SKBR-3.
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.
  • Presence of HER-2/neu amplification was associated with poor carcinoma-specific survival (P=0.0089).
  • HER-2/neu targeting antibody trastuzumab inhibited the growth of a p185(HER-2/neu) overexpressing gastric and breast carcinoma cell lines (N87 and SKBR-3) with equal efficacy.
  • CONCLUSIONS: HER-2/neu amplification is common in the intestinal type of gastric carcinoma, and it is associated with a poor outcome.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668283.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


38. Liang HH, Wu CH, Tam KW, Chai CY, Lin SE, Chen SC: Thyroid metastasis in a patient with hepatocellular carcinoma: case report and review of literature. World J Surg Oncol; 2007;5:144
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid metastasis in a patient with hepatocellular carcinoma: case report and review of literature.
  • Although lung, renal, and breast cancer are probably the most common primary sites, a number of cancers have been reported to metastasize to the thyroid synchronously with diagnosis of primary tumor or years after apparently curative treatment.
  • CASE PRESENTATION: We report a rare case of a hepatocellular carcinoma metasatic to the thyroid.
  • The patient presented seven months after original diagnosis and treatment with hepatic lobectomy with multiple neck lesions producing a mass effect on the trachea and bilateral lymphadenopathy.
  • Fine-needle aspiration revealed highly anaplastic carcinoma, and immunohistochemistry confirmed hepatocellular carcinoma.
  • In cases where cytology or histology is not diagnostic, immunohistochemistry may be definitive in making the diagnosis.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2004 Dec;9(6):515-9 [15616884.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Thyroid. 1998 Feb;8(2):149-53 [9510123.001]
  • [Cites] Int J Clin Oncol. 2007 Feb;12(1):63-7 [17380445.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Radiat Med. 2001 Jan-Feb;19(1):43-6 [11305618.001]
  • [Cites] J Formos Med Assoc. 2001 Feb;100(2):106-12 [11393097.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):911-21 [12472285.001]
  • [Cites] J Am Coll Surg. 2005 Feb;200(2):203-7 [15664095.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):37-41 [9448014.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):236-41 [15670202.001]
  • (PMID = 18157914.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2246133
  •  go-up   go-down


39. Baloch ZW, LiVolsi VA: Unusual tumors of the thyroid gland. Endocrinol Metab Clin North Am; 2008 Jun;37(2):297-310, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include follicular adenoma and carcinoma (Hürthle and non-Hürthle), and papillary carcinoma and its variants.
  • Other primary epithelial tumors include medullary carcinoma, mixed medullary and follicular carcinomas, insular and poorly differentiated carcinoma, anaplastic carcinoma, and the least common squamous carcinoma and related tumors.
  • The secondary tumors represent metastatic tumors to the thyroid usually originating in lung, kidney, and breast.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / pathology. Rare Diseases / diagnosis. Rare Diseases / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Disease Progression. Humans. Neoplasm Staging. Prognosis. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502328.001).
  • [ISSN] 0889-8529
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


40. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res; 2009 Dec 1;15(23):7153-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, however, in breast, prostate, colon, and thyroid (papillary, follicular, anaplastic, and medullary) carcinoma cell lines, this combination triggered synergistic cytotoxicity, and increased expression of p53, p21, Hdm2, Bax, Noxa, PUMA, and cleavage of caspase-3 and poly ADP ribose polymerase.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6347-55 [11086072.001]
  • [Cites] Cell Death Differ. 2010 Jan;17(1):86-92 [19543236.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5556-71 [12897130.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1646-56 [9880544.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):439-44 [15542427.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1461-6 [15608685.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3609-17 [16081689.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1092-100 [16234364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1341-7 [17073596.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3177-88 [17185464.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):950-68 [17546631.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • (PMID = 19934289.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA050947-17A1; United States / NCI NIH HHS / CA / R01 CA050947; United States / NCI NIH HHS / CA / R01 CA050947-17A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Imidazoles; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS145802; NLM/ PMC3672410
  •  go-up   go-down


41. Stulp RP, Herkert JC, Karrenbeld A, Mol B, Vos YJ, Sijmons RH: Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum. Hered Cancer Clin Pract; 2008;6(1):15-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, she had been diagnosed with an undifferentiated carcinoma of the thyroid and an adenoma of her coecum.
  • Although the thyroid carcinoma was not MSI-high (1 out of 5 microsatellites instable), it did show complete loss of immunohistochemical expression for the MSH2 protein, suggesting that this tumour was not coincidental.
  • Although the risks for some tumour types, including breast cancer, soft tissue sarcoma and prostate cancer, are not significantly increased in Lynch syndrome, MMR deficiency in the presence of a corresponding germline defect has been demonstrated in incidental cases of a growing range of tumour types, which is reviewed in this paper.
  • Together with a previously reported case, our findings show that anaplastic thyroid carcinoma can develop in the setting of Lynch syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4486-94 [15483016.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Fam Cancer. 2008;7(3):191-8 [18049911.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Apr;47(4):326-32 [18181177.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):62-72 [17851451.001]
  • [Cites] Hum Mutat. 2007 Nov;28(11):1084-90 [17557300.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):543-5 [17666659.001]
  • [Cites] Fam Cancer. 2007;6(1):141-5 [17051350.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):e83 [17601929.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2349-56 [17440981.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Gut. 2006 Dec;55(12):1781-8 [16636019.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):135-6 [9326924.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):269-78 [9087566.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Cancer. 1996 May 1;77(9):1836-43 [8646682.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Fam Cancer. 2004;3(2):123-7 [15340263.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):981-9 [15143336.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1262-9 [15098177.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):954-64 [15077197.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):576-85 [14762794.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Fam Cancer. 2001;1(2):101-5 [14574005.001]
  • [Cites] Histopathology. 2003 Sep;43(3):297-9 [12940783.001]
  • [Cites] Am J Med Genet A. 2003 Aug 30;121A(2):159-62 [12910497.001]
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):213-6 [12549480.001]
  • [Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4074-80 [11600610.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4541-4 [11389087.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):87-91 [10206076.001]
  • [Cites] J Med Genet. 2005 Jun;42(6):491-6 [15937084.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4689-93 [16000562.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):415-21 [16083698.001]
  • [Cites] Eur J Hum Genet. 2006 May;14(5):561-6 [16418736.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):358-61 [16507833.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):437-41 [10598809.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1719-23 [10763829.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):353-5 [11066081.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):195-9 [16372347.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):193-6 [16405554.001]
  • [Cites] Am J Med Genet A. 2005 Dec 1;139A(2):96-105; discussion 96 [16283678.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1322-6 [16311127.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1886-91 [16144131.001]
  • (PMID = 19706203.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2735069
  •  go-up   go-down


42. Buła G, Waler J, Niemiec A, Koziołek H, Bichalski W, Gawrychowski J: Diagnosis of metastatic tumours to the thyroid gland by fine needle aspiration biopsy. Endokrynol Pol; 2010 Sep-Oct;61(5):427-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of metastatic tumours to the thyroid gland by fine needle aspiration biopsy.
  • RESULTS: Among 7 patients with thyroid metastases from renal clear cell carcinoma, as diagnosed postoperatively, cytology of the thyroid material obtained through FNA revealed follicular tumour in 3 (43%) patients, tumour cells in 2 (28.5%) and atypical cells in the other 2 (28.5%).
  • Intraoperative histopathology confirmed the presence of metastasis from renal clear cell carcinoma (1) and indicated thyroid medullary cancer (1), follicular tumour (4), or trabecular adenoma with necrosis (1).
  • Among two patients with thyroid metastases from breast cancer, cytology confirmed a metastasis from breast cancer in one (the woman was disqualified for surgical treatment) and indicated follicular tumour in one.
  • Intraoperative histopathology suggested thyroid anaplastic cancer.
  • CONCLUSIONS: Follicular tumour diagnosed by fine needle aspiration biopsy in patients after treatment for other cancers, especially renal clear cell carcinoma, should alert the surgeon to the possibility that it could be a metastasis of this cancer to the thyroid gland.
  • [MeSH-minor] Adenoma / pathology. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Neuroendocrine. Female. Humans. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Monitoring, Intraoperative / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049452.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] Thyroid cancer, medullary
  •  go-up   go-down


43. Madrazo J, García-Fernández RA, García-Iglesias MJ, Durán AJ, Espinosa J, Pérez-Martínez C: The role of CD44 adhesion factor in canine mammary carcinomas. Vet J; 2009 Jun;180(3):371-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD44 is an adhesion molecule implicated in the progression of human breast cancer.
  • Complex (grade I) and anaplastic (grade III) carcinomas exhibited more intense expression of this antigen than did some tubulopapillary and most solid carcinomas (grade II).
  • Although reduced CD44 expression was associated with infiltrative growth and vascular invasion in solid carcinomas, intense expression was also observed in anaplastic tumours.
  • [MeSH-major] Antigens, CD44 / metabolism. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary Neoplasms, Animal / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299241.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44
  •  go-up   go-down


44. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


45. Hornick JL, Dal Cin P, Fletcher CD: Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol; 2009 Apr;33(4):542-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated 350 tumors: 136 ES, including 64 conventional ("distal") ES, 64 proximal-type ES, and 8 with hybrid features of conventional and proximal-type ES; 54 metastatic carcinomas (22 from lung, 6 breast, 6 stomach, 5 colorectum, 5 kidney, 5 prostate, 5 pancreas); 12 metastatic testicular embryonal carcinomas; 20 metastatic melanomas; 20 epithelioid mesotheliomas; 20 epithelioid angiosarcomas; 10 epithelioid hemangioendotheliomas; 24 epithelioid malignant peripheral nerve sheath tumors (MPNST); 22 myoepithelial carcinomas of soft tissue; 7 anaplastic large cell lymphomas; 5 histiocytic sarcomas; and 10 control MRT of infancy (4 brain, 3 liver, 2 soft tissue, 1 kidney).
  • Immunostaining for INI1 can be used to confirm the diagnosis of ES in the appropriate context.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Carcinoma, Embryonal / metabolism. Carcinoma, Embryonal / secondary. Female. Humans. Immunohistochemistry / methods. Infant. Male

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033866.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


46. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res; 2006 Feb 15;66(4):2153-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of Foxm1 is found in a variety of distinct human cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas, ductal breast carcinomas, and anaplastic astrocytomas and glioblastomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Forkhead Transcription Factors / physiology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489016.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 54687-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNA2 protein, human; 0 / CCNB1 protein, human; 0 / Ccnb1 protein, mouse; 0 / Cyclin A; 0 / Cyclin A2; 0 / Cyclin B; 0 / Cyclin B1; 0 / DNA, Neoplasm; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Foxm1 protein, mouse; 0 / RNA, Small Interfering; 3IN71E75Z5 / Urethane
  •  go-up   go-down


47. Vaiman M, Olevson Y, Habler L, Kessler A, Zehavi S, Sandbank J: Diagnostic value of estrogen receptors in thyroid lesions. Med Sci Monit; 2010 Jul;16(7):BR203-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL/METHODS: Immunohistochemical stains were performed for both ERalpha and ERbeta, for evaluation of immunoreactivity in 296 thyroid tissue samples that consisted of 150 goiters, 90 papillary carcinomas, 19 follicular adenomas, 15 Hurtle cell adenomas, 6 Hashimoto thyroiditis, 5 anaplastic carcinomas, 4 medullary carcinomas, 4 follicular carcinomas, 2 Hurtle cell carcinomas, and 1 squamous cell carcinoma of the thyroid.
  • [MeSH-major] Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Goiter, Nodular / diagnosis. Thyroid Gland / metabolism. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581768.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  •  go-up   go-down


48. Zhang MQ, Lennerz JK, Dehner LP, Brunt LM, Wang HL: Granulomatous inflammatory pseudotumor of the spleen: association with Epstein-Barr virus. Appl Immunohistochem Mol Morphol; 2009 May;17(3):259-63
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 74-year-old woman with a clinical history of invasive ductal carcinoma of the breast was found to have a splenic mass during a routine radiographic survey.
  • No spindle cell component was evident on light microscopic examination or by immunohistochemical staining for smooth muscle actin, anaplastic lymphoma kinase, or follicular dendritic cell markers CD21 and CD35.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987550.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


49. Ambrosini V, Quarta C, Zinzani PL, Nanni C, Fini M, Torricelli P, Giavaresi G, D'Errico-Grigioni A, Malvi D, Franchi R, Fanti S: 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. Q J Nucl Med Mol Imaging; 2010 Dec;54(6):689-97
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Food and Drug Administration (FDA) approved the use of Sorafenib, an oral multikinase inhibitor, for advanced renal carcinoma and unresectable hepatocellular carcinoma.
  • On-going studies are investigating the efficacy of Sorafenib in other solid tumours such as melanoma and non-small cells lung carcinoma and pre-clinical models showed the efficacy of treatment with Sorafenib in murine models of renal cells carcinoma, breast cancer, colon carcinoma and melanoma.
  • The aim of the present study was to assess the efficacy of Sorafenib in murine models of human anaplastic large cells lymphoma (ALCL) and Hodgkin lymphoma (HD).

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639808.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


50. Paes JE, Ringel MD: Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am; 2008 Jun;37(2):375-87, viii-ix
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These genetic abnormalities have been particularly associated with follicular thyroid neoplasia and anaplastic thyroid cancer, suggesting an important role for PI3K signaling in these disorders.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Mol Endocrinol. 2005 Nov;19(11):2748-59 [15994200.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Org Lett. 2006 Jan 19;8(2):321-4 [16408905.001]
  • [Cites] Endocrinology. 2006 Feb;147(2):1014-9 [16254036.001]
  • [Cites] Mol Pharmacol. 2007 Nov;72(5):1124-31 [17673571.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2451-8 [17660507.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1475-9 [16432179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1780-5 [16446424.001]
  • [Cites] Thyroid. 2006 Jan;16(1):17-23 [16487009.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1877-83 [16287065.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Genes Dev. 2006 Jun 15;20(12):1569-74 [16778075.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20666-72 [16717100.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4463-75 [16777971.001]
  • [Cites] Bioorg Med Chem. 2006 Oct 15;14(20):6847-58 [16837202.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):959-66 [17283127.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):942-7 [16946008.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):917-31 [17386267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5569-74 [17376864.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3109-14 [17545512.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90 [17426084.001]
  • [Cites] Trends Biochem Sci. 2007 Jul;32(7):342-9 [17561399.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8002-6 [17804710.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):8024-32 [10637513.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8271-4 [10722653.001]
  • [Cites] Kaohsiung J Med Sci. 2000 Jan;16(1):9-12 [10741010.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1693-700 [10793080.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47720-5 [15364915.001]
  • [Cites] J Endocrinol. 2004 Nov;183(2):249-56 [15531713.001]
  • [Cites] Mol Endocrinol. 2005 Jan;19(1):102-12 [15388791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7 [15647370.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1633-9 [10861290.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3146-55 [10918569.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Sep;35(1):74-80 [12203792.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):182-92 [12203783.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39858-66 [12176997.001]
  • [Cites] Thyroid. 2002 Nov;12(11):963-9 [12490073.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 31;301(1):50-3 [12535639.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):318-27 [12569555.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1382-94 [12738763.001]
  • [Cites] J Med Genet. 2004 Mar;41(3):161-70 [14985374.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] J Med Genet. 2004 May;41(5):323-6 [15121767.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2982-8 [15181088.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41189-96 [15262962.001]
  • [Cites] Cell Mol Biol. 1991;37(8):813-21 [1807790.001]
  • [Cites] Nature. 1994 Aug 18;370(6490):527-32 [8052307.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4710-3 [9354427.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Nov;23(3):239-43 [9790504.001]
  • [Cites] Curr Biol. 1998 Dec 17-31;8(25):1366-75 [9889098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 [9990064.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5 [10200246.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4891-8 [10490823.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):1163-70 [15522933.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):13-24 [15808505.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93 [15928251.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4456-63 [16002527.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R609-16 [16168105.001]
  • (PMID = 18502332.001).
  • [ISSN] 0889-8529
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102572-04; United States / NCI NIH HHS / CA / R01 CA102572; United States / NCI NIH HHS / CA / 5 R01 CA102572-02; United States / NCI NIH HHS / CA / R01 CA102572-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 72
  • [Other-IDs] NLM/ NIHMS55687; NLM/ PMC2446602
  •  go-up   go-down


51. Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, Dardano A, Faviana P, Madec S, Di Virgilio F, Monzani F: Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology; 2008 Jan;149(1):389-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies showed that P2X(7) is overexpressed in chronic lymphocytic leukemia and breast and prostate cancer.
  • P2X(7) receptor message and protein expression and functional activity were tested in two cell lines (FB1 and FB2) established from either anaplastic or papillary primary thyroid cancer and in several histological samples of human papillary cancer.
  • We show here that human thyroid papillary carcinoma, whether of the classical or follicular variant, expresses the P2X(7) receptor (P2X(7)R) to a much higher level than normal thyroid tissue.
  • Finally, the thyroid carcinoma cell lines had at least a 3-fold higher intracellular ATP concentration and maintained at least a 3-fold higher extracellular ATP level, compared with control cells.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / physiology. Carcinoma, Papillary / genetics. Receptors, Purinergic P2 / genetics. Receptors, Purinergic P2 / physiology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947359.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP06070
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / P2RX7 protein, human; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


52. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


53. Rohana A, Hisham AN: Emergency thyroid surgery: a surgical challenge. Asian J Surg; 2009 Apr;32(2):81-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A histopathology report confirmed 16 patients had multinodular goiters, eight patients had papillary thyroid carcinomas, seven patients had anaplastic cancers, four patients had follicular thyroid carcinomas, two patients had thyroid lymphoma, one patient had medullary carcinoma, one patient had sarcoma and one patient had thyroid abscess.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423453.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


54. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol; 2010 Oct;66(5):927-33
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):581-6 [9773800.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):285-9 [10359149.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Eur J Pharmacol. 2001 Jan 19;412(1):21-5 [11166732.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] Onkologie. 1983 Apr;6(2):58-61 [6223253.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):382-8 [3417367.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):382-3 [2407368.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4837-44 [1893376.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90 [8384328.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1696-9 [7691116.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(2):215-20 [8686548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309-15 [8738036.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):587-90; discussion 590-1 [8837815.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):161-7 [9266454.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-52-S12-55 [9331122.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):307-16 [9488600.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • (PMID = 20107803.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572-26; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS335377; NLM/ PMC3265324
  •  go-up   go-down


55. Shiller SM, Konduri K, Harshman LK, Welch BJ, O'Brien JC: Recurrent thyroid cancer with changing histologic features. Proc (Bayl Univ Med Cent); 2010 Jul;23(3):304-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 57-year-old woman diagnosed with breast cancer and a thyroid mass that was suspicious for cancer.
  • The breast cancer was estrogen and progesterone receptor negative, HER2/neu borderline, with a high proliferative index.
  • After 2½ years, the cancer recurred as a more highly aggressive, undifferentiated anaplastic thyroid carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Aug;24(8):923-33 [10865036.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8 [7883548.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1083-9 [11061600.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4081-6 [11095436.001]
  • [Cites] Clin Nucl Med. 2001 Mar;26(3):198-201 [11245109.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1848-53 [12085174.001]
  • [Cites] Clin Nucl Med. 2003 Jun;28(6):527-8 [12917548.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):381-8 [15650765.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Mol Cancer Res. 2009 Oct;7(10):1645-54 [19825993.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Mayo Clin Proc. 1985 Jan;60(1):51-8 [3965822.001]
  • [Cites] Annu Rev Med. 1994;45:45-52 [8198395.001]
  • [Cites] Oncogene. 1997 Feb 13;14(6):729-40 [9038381.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1083-91 [19095376.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • (PMID = 21240322.001).
  • [ISSN] 1525-3252
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2900987
  •  go-up   go-down


56. Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM: Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg; 2007 Oct;133(10):1022-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.
  • The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.
  • Use of this combination treatment of gefitinib and doxorubicin may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma / drug therapy. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Culture Media. Doxorubicin / administration & dosage. Drug Resistance, Multiple. Flow Cytometry. Fluorescent Antibody Technique. Humans. In Situ Nick-End Labeling. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938326.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Culture Media; 0 / Neoplasm Proteins; 0 / Quinazolines; 0 / RNA, Neoplasm; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


57. Hemminki K, Eng C, Chen B: Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab; 2005 Oct;90(10):5747-53
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Systematized Nomenclature of Medicine histology was available from 1993 onward, with 1449 papillary, 288 follicular, 148 anaplastic, and 68 Hurthle cell tumors.
  • RESULTS: The familial risk for papillary carcinoma was 3.21 and 6.24 when a parent and a sibling, respectively, were diagnosed with thyroid cancers.
  • Associations found in single comparisons with papillary thyroid cancer and other sites included right-sided colon, breast, ovarian, and kidney cancers.
  • The high risk for papillary carcinoma among women requires clinical attention, although the absolute risks for this rare cancer are still low.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030170.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer; 2008 Dec;15(4):1069-74
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this study were to characterize the density of TAMs in well-differentiated (WDTC), poorly differentiated (PDTC), and anaplastic thyroid cancers (ATC) and to correlate TAM density with clinicopathologic parameters.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Sep;17(3):445-51 [10938382.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8429-32 [17875679.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):251-2 [12398887.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):408-16 [12519884.001]
  • [Cites] Breast Cancer Res. 2003;5(2):83-8 [12631386.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5958-67 [15184868.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Lab Invest. 1994 Jul;71(1):5-16 [7518882.001]
  • [Cites] J Cancer Res Clin Oncol. 1994;120(11):651-6 [7525593.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):467-70 [7485734.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1615-20 [9141559.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):442-7 [9874430.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):425-31 [16012726.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6521-9 [16818623.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):365-72 [17167977.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):122-9 [17210691.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):947-56 [12213723.001]
  • (PMID = 18719091.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA050706-19; United States / NCI NIH HHS / CA / R01 CA050706; United States / NCI NIH HHS / CA / NIH CA50706; United States / NCI NIH HHS / CA / R01 CA050706-19
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS81725; NLM/ PMC2648614
  •  go-up   go-down


59. Senter PD: Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol; 2009 Jun;13(3):235-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include SGN-35, an ADC directed against the CD30-positive malignancies such as Hodgkin's disease and anaplastic large cell lymphoma, and trastuzumab-DM1 which has shown activity in metastatic breast carcinoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414278.001).
  • [ISSN] 1879-0402
  • [Journal-full-title] Current opinion in chemical biology
  • [ISO-abbreviation] Curr Opin Chem Biol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cytotoxins; 0 / Immunoconjugates
  • [Number-of-references] 74
  •  go-up   go-down


60. Krishnan C, Moline S, Anders K, Warnke RA: Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma. J Clin Oncol; 2009 May 20;27(15):2563-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular ALK-positive anaplastic large-cell lymphoma mimicking inflammatory breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adult. Antigens, CD30 / biosynthesis. Biomarkers, Tumor / metabolism. Cellulitis / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inflammation / pathology. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364961.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


61. Meng YX, Jiang Y, Lu ZH, Chen J: [Epithelial neoplasms associated with osteoclast-like giant cells]. Zhonghua Bing Li Xue Za Zhi; 2010 Sep;39(9):642-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology. Thyroid Neoplasms / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Renal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / pathology. Female. Humans. Ovarian Neoplasms / pathology. Thyroid Carcinoma, Anaplastic. Tongue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092601.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] Papillary renal cell carcinoma, sporadic
  •  go-up   go-down






Advertisement